Misplaced Pages

Pneumococcal polysaccharide vaccine

Vaccine description
Target	23 serotypes of Streptococcus pneumoniae
Vaccine type	Polysaccharide
Clinical data
Trade names	Pneumovax 23
Other names	PPSV, PPV-23, PPSV23
AHFS/Drugs.com	Monograph
MedlinePlus	a607022
License data	US DailyMed: Pneumococcal vaccine polyvalent
Pregnancy category	AU: B2
Routes of administration	Intramuscular
ATC code	J07AL01 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
ChemSpider	none
KEGG	D08776
(what is this?)  (verify)

Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. It is given by intramuscular or subcutaneous injection.

The polysaccharide antigens were used to induce type-specific antibodies that enhanced opsonization, phagocytosis, and killing of Streptococcus pneumoniae (pneumococcal) bacteria by phagocytic immune cells. The pneumococcal polysaccharide vaccine is widely used in high-risk adults.

First used in 1945, the tetravalent vaccine was not widely distributed, since its deployment coincided with the discovery of penicillin. In the 1970s, Robert Austrian championed the manufacture and distribution of a 14-valent pneumococcal polysaccharide vaccine. This evolved in 1983 to a 23-valent formulation (PPSV23). A significant breakthrough affecting the burden of pneumococcal disease was the licensing of a protein conjugate heptavalent vaccine (PCV7) beginning in February 2000.

Medical uses

In the United States, pneumococcal vaccine, polyvalent is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). It is approved for use in people 50 years of age or older and people aged two years of age or older who are at increased risk for pneumococcal disease. The World Health Organization (WHO) recommendations are similar. The WHO does not recommend use of pneumococcal polysaccharide vaccine in routine childhood immunization programs. The recommendations in the UK are similar, but include people with occupational hazards.

Pneumococcal vaccine may be beneficial to control exacerbations of chronic obstructive pulmonary disease (COPD).

The pneumococcal polysaccharide vaccine is important for those with HIV/AIDS. In Canadian patients infected with HIV, the vaccine has been reported to decrease the incidence of invasive pneumococcal disease from 768 per 100,000 person–years to 244 per 100,000 patient–years. Because of the low level of evidence for benefit, 2008 WHO guidelines do not recommend routine immunization with PPV-23 for HIV patients, and suggests preventing pneumococcal disease indirectly with trimethoprim–sulfamethoxazole chemoprophylaxis and antiretrovirals. While the U.S. Centers for Disease Control and Prevention (CDC) recommends immunization in all patients infected with HIV.

Adverse events

The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).

Vaccination schedule

Adults and children over two years of age

The 23-valent vaccine (for example, Pneumovax 23) is effective against 23 different pneumococcal capsular types (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F), and so covers 90 percent of the types found in pneumococcal bloodstream infections.

Young children

Children under the age of two years fail to mount an adequate response to the 23-valent adult vaccine, and instead a 13-valent pneumococcal conjugated vaccine (PCV13; for example, Prevnar 13) is used instead. PCV13 replaced PCV7, adding six new serotypes to the vaccine. While this covers only thirteen strains out of more than ninety strains, these thirteen strains caused 80–90 percent of cases of severe pneumococcal disease in the U.S. before introduction of the vaccine, and it is considered to be nearly 100 percent effective against these strains.

Special risk-groups

Children at special risk (e.g., sickle cell disease and those without a functioning spleen) require additional protection using the PCV13, with the more extensive PPSV-23 given after the second year of life or two months after the PCV13 dose:

References

1. "Pneumococcal 23-polyvalent vaccine (Pneumovax 23) Use During Pregnancy". Drugs.com. 7 October 2019. Retrieved 14 July 2020.
2. ^ "Pneumovax 23- pneumococcal vaccine polyvalent injection, solution". DailyMed. Retrieved 11 January 2022.
3. ^ "Pneumovax 23 - Pneumococcal Vaccine, Polyvalent". U.S. Food and Drug Administration (FDA). 28 October 2021. STN BLA 101094. This article incorporates text from this source, which is in the public domain.
4. ^ Siemieniuk RA, Gregson DB, Gill MJ (November 2011). "The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study". BMC Infectious Diseases. 11: 314. doi:10.1186/1471-2334-11-314. PMC 3226630. PMID 22078162.
5. Macleod CM, Hodges RG, Heidelberger M, Bernhard WG (November 1945). "Prevention of Pneumococcal Pneumonia by Immunization with Specific Capsular Polysaccharides". The Journal of Experimental Medicine. 82 (6): 445–465. doi:10.1084/jem.82.6.445. PMC 2135567. PMID 19871511.
6. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, et al. (1976). "Prevention of pneumococcal pneumonia by vaccination". Transactions of the Association of American Physicians. 89: 184–194. PMID 14433.
7. Klein JO, Plotkin SA (2007). "Robert Austrian: 1917-2007". Clin Infect Dis. 45: 2–3. doi:10.1086/520068.
8. Kim NH, Lee J, Lee SJ, Lee H, Kim KH, Park SE, et al. (November 2007). "Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children". Vaccine. 25 (45): 7858–7865. doi:10.1016/j.vaccine.2007.08.022. PMID 17931753.
9. "Pneumococcal Vaccination - What You Should Know". Centers for Disease Control and Prevention (CDC). 6 December 2017. Archived from the original on 12 November 2019. Retrieved 11 November 2019.
10. ^ World Health Organization (2008). "23-valent pneumococcal polysaccharide vaccine : WHO position paper". Wkly. Epidemiol. Rec. 83 (42): 373–84. hdl:10665/241217. PMID 18927997.
11. "World Health Organization. Pneumococcal vaccines". Archived from the original on 6 March 2002. Retrieved 29 May 2009.
12. "Who should have the pneumococcal vaccine?". NHS. 2019. Retrieved 7 October 2020.
13. Froes F, Roche N, Blasi F (2017). "Pneumococcal vaccination and chronic respiratory diseases". Int J Chron Obstruct Pulmon Dis. 12: 3457–3468. doi:10.2147/COPD.S140378. PMC 5723118. PMID 29255353.
14. "Pneumococcal Vaccine Timing for Adults" (PDF). Centers for Disease Control and Prevention. 16 March 2020. Retrieved 14 July 2020.
15. Childhood Pneumococcal Disease Archived 25 October 2006 at the Wayback Machine – information on the disease and the Prevnar vaccine, from the Victoria State (Australia) government.
16. "Pneumococcal: the green book, chapter 25". Immunisation against infectious disease. Public Health England. 2013. Gateway 2017624. Archived from the original on 12 November 2019.

Further reading

• Moberley S, Holden J, Tatham DP, Andrews RM (2013). "Vaccines for preventing pneumococcal infection in adults". Cochrane Database Syst Rev. 1 (1): CD000422. doi:10.1002/14651858.CD000422.pub3. PMC 7045867. PMID 23440780.
• World Health Organization (September 2009). The immunological basis for immunization series: module 12: pneumococcal vaccines. World Health Organization (WHO). hdl:10665/44135. ISBN 9789241598217.
• Ramsay M, ed. (January 2018). "Chapter 25: Pneumococcal". Immunisation against infectious disease. Public Health England.
• Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 17: Pneumococcal Disease". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-0990449119.
• Roush SW, Baldy LM, Hall MA, eds. (9 January 2020). "Chapter 11: Pneumococcal". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: Centers for Disease Control and Prevention (CDC).
• World Health Organization (2008). "23-valent pneumococcal polysaccharide vaccine : WHO position paper". Wkly. Epidemiol. Rec. 83 (42): 373–84. hdl:10665/241217. PMID 18927997.

External links

• Pneumococcal Disease World Health Organization (WHO)
• "Pneumococcal Polysaccharide Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). October 2019.

• Medicine
• Viruses

• Vaccines